Association of matrix Metalloproteinase-9 rs3918242 promoter genotypes with colorectal cancer risk

Ming Hsien Wu, Huey En Tzeng, Cheng Nan Wu, Te Cheng Yueh, Yen Chun Peng, Chun Hao Tsai, Yun Chi Wang, Tao Wei Ke, Jen Sheng Pei, Wen Shin Chang, Chia Wen Tsai, Da Tian Bau

Research output: Contribution to journalArticle

Abstract

Background/Aim: Matrix metalloproteinase-9 (MMP-9) is responsible for modifying extracellular components and plays a crucial role in the metastatic behavior of cancer. This study aimed at examining the role of MMP-9 rs3918242 genotypes on colorectal cancer (CRC) risk. Materials and Methods: A total of 362 CRC patients and 362 healthy subjects in Taiwan, were examined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. Results: The MMP-9 rs3918242 TT genotype carriers had a slightly increased risk of CRC compared to CC carriers (p=0.1642, OR=1.88, 95% CI=0.84-4.16). Patients of CT/TT genotypes were on significantly higher risk of metastasis (p=0.0027) than those of CC genotype. No obvious association was found between MMP-9 genotype and CRC risk among ever-smokers, non-smokers, non-alcohol drinkers or alcohol drinkers. No significant correlation was observed between MMP-9 genotypic distributions with age, gender, tumor size or location. Conclusion: MMP-9 rs3918242 genotypes may interact with BMI to serve as a predictor for higher CRC risk, and independently as a predictor for metastasis.

Original languageEnglish
Pages (from-to)6523-6529
Number of pages7
JournalAnticancer Research
Volume39
Issue number12
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Matrix Metalloproteinase 9
Colorectal Neoplasms
Genotype
Neoplasm Metastasis
Age Distribution
Taiwan
Restriction Fragment Length Polymorphisms
Neoplasms
Healthy Volunteers
Alcohols
Polymerase Chain Reaction

Keywords

  • Case-control study
  • Colorectal cancer
  • Genotype
  • MMP-9
  • Polymorphism
  • Taiwan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Association of matrix Metalloproteinase-9 rs3918242 promoter genotypes with colorectal cancer risk. / Wu, Ming Hsien; Tzeng, Huey En; Wu, Cheng Nan; Yueh, Te Cheng; Peng, Yen Chun; Tsai, Chun Hao; Wang, Yun Chi; Ke, Tao Wei; Pei, Jen Sheng; Chang, Wen Shin; Tsai, Chia Wen; Bau, Da Tian.

In: Anticancer Research, Vol. 39, No. 12, 01.01.2019, p. 6523-6529.

Research output: Contribution to journalArticle

Wu, MH, Tzeng, HE, Wu, CN, Yueh, TC, Peng, YC, Tsai, CH, Wang, YC, Ke, TW, Pei, JS, Chang, WS, Tsai, CW & Bau, DT 2019, 'Association of matrix Metalloproteinase-9 rs3918242 promoter genotypes with colorectal cancer risk', Anticancer Research, vol. 39, no. 12, pp. 6523-6529. https://doi.org/10.21873/anticanres.13867
Wu, Ming Hsien ; Tzeng, Huey En ; Wu, Cheng Nan ; Yueh, Te Cheng ; Peng, Yen Chun ; Tsai, Chun Hao ; Wang, Yun Chi ; Ke, Tao Wei ; Pei, Jen Sheng ; Chang, Wen Shin ; Tsai, Chia Wen ; Bau, Da Tian. / Association of matrix Metalloproteinase-9 rs3918242 promoter genotypes with colorectal cancer risk. In: Anticancer Research. 2019 ; Vol. 39, No. 12. pp. 6523-6529.
@article{cf187c838b834c27a1a06cbd802245ef,
title = "Association of matrix Metalloproteinase-9 rs3918242 promoter genotypes with colorectal cancer risk",
abstract = "Background/Aim: Matrix metalloproteinase-9 (MMP-9) is responsible for modifying extracellular components and plays a crucial role in the metastatic behavior of cancer. This study aimed at examining the role of MMP-9 rs3918242 genotypes on colorectal cancer (CRC) risk. Materials and Methods: A total of 362 CRC patients and 362 healthy subjects in Taiwan, were examined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. Results: The MMP-9 rs3918242 TT genotype carriers had a slightly increased risk of CRC compared to CC carriers (p=0.1642, OR=1.88, 95{\%} CI=0.84-4.16). Patients of CT/TT genotypes were on significantly higher risk of metastasis (p=0.0027) than those of CC genotype. No obvious association was found between MMP-9 genotype and CRC risk among ever-smokers, non-smokers, non-alcohol drinkers or alcohol drinkers. No significant correlation was observed between MMP-9 genotypic distributions with age, gender, tumor size or location. Conclusion: MMP-9 rs3918242 genotypes may interact with BMI to serve as a predictor for higher CRC risk, and independently as a predictor for metastasis.",
keywords = "Case-control study, Colorectal cancer, Genotype, MMP-9, Polymorphism, Taiwan",
author = "Wu, {Ming Hsien} and Tzeng, {Huey En} and Wu, {Cheng Nan} and Yueh, {Te Cheng} and Peng, {Yen Chun} and Tsai, {Chun Hao} and Wang, {Yun Chi} and Ke, {Tao Wei} and Pei, {Jen Sheng} and Chang, {Wen Shin} and Tsai, {Chia Wen} and Bau, {Da Tian}",
year = "2019",
month = "1",
day = "1",
doi = "10.21873/anticanres.13867",
language = "English",
volume = "39",
pages = "6523--6529",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Association of matrix Metalloproteinase-9 rs3918242 promoter genotypes with colorectal cancer risk

AU - Wu, Ming Hsien

AU - Tzeng, Huey En

AU - Wu, Cheng Nan

AU - Yueh, Te Cheng

AU - Peng, Yen Chun

AU - Tsai, Chun Hao

AU - Wang, Yun Chi

AU - Ke, Tao Wei

AU - Pei, Jen Sheng

AU - Chang, Wen Shin

AU - Tsai, Chia Wen

AU - Bau, Da Tian

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background/Aim: Matrix metalloproteinase-9 (MMP-9) is responsible for modifying extracellular components and plays a crucial role in the metastatic behavior of cancer. This study aimed at examining the role of MMP-9 rs3918242 genotypes on colorectal cancer (CRC) risk. Materials and Methods: A total of 362 CRC patients and 362 healthy subjects in Taiwan, were examined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. Results: The MMP-9 rs3918242 TT genotype carriers had a slightly increased risk of CRC compared to CC carriers (p=0.1642, OR=1.88, 95% CI=0.84-4.16). Patients of CT/TT genotypes were on significantly higher risk of metastasis (p=0.0027) than those of CC genotype. No obvious association was found between MMP-9 genotype and CRC risk among ever-smokers, non-smokers, non-alcohol drinkers or alcohol drinkers. No significant correlation was observed between MMP-9 genotypic distributions with age, gender, tumor size or location. Conclusion: MMP-9 rs3918242 genotypes may interact with BMI to serve as a predictor for higher CRC risk, and independently as a predictor for metastasis.

AB - Background/Aim: Matrix metalloproteinase-9 (MMP-9) is responsible for modifying extracellular components and plays a crucial role in the metastatic behavior of cancer. This study aimed at examining the role of MMP-9 rs3918242 genotypes on colorectal cancer (CRC) risk. Materials and Methods: A total of 362 CRC patients and 362 healthy subjects in Taiwan, were examined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. Results: The MMP-9 rs3918242 TT genotype carriers had a slightly increased risk of CRC compared to CC carriers (p=0.1642, OR=1.88, 95% CI=0.84-4.16). Patients of CT/TT genotypes were on significantly higher risk of metastasis (p=0.0027) than those of CC genotype. No obvious association was found between MMP-9 genotype and CRC risk among ever-smokers, non-smokers, non-alcohol drinkers or alcohol drinkers. No significant correlation was observed between MMP-9 genotypic distributions with age, gender, tumor size or location. Conclusion: MMP-9 rs3918242 genotypes may interact with BMI to serve as a predictor for higher CRC risk, and independently as a predictor for metastasis.

KW - Case-control study

KW - Colorectal cancer

KW - Genotype

KW - MMP-9

KW - Polymorphism

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=85076315207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076315207&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13867

DO - 10.21873/anticanres.13867

M3 - Article

C2 - 31810917

AN - SCOPUS:85076315207

VL - 39

SP - 6523

EP - 6529

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -